Rezolute, Inc. — Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended December 31, 2022; filed February 10, 2023. Rezolute is a clinical-stage biopharmaceutical company developing RZ358 for congenital hyperinsulinism and RZ402, an oral plasma kallikrein inhibitor, for diabetic macular edema (DME). The company has no commercial products and has not generated revenue.
Financial results and position
| Metric | Three months ended Dec. 31, 2022 | Six months ended Dec. 31, 2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development | $10.9 million | $18.6 million |
| General and administrative | $3.4 million | $6.0 million |
| Operating loss | $14.4 million | $24.6 million |
| Net loss | $13.6 million | $23.4 million |
| Net loss per share, basic and diluted | $0.26 | $0.46 |
| Net cash used in operating activities | Six-month period: $15.1 million |
At December 31, 2022, cash and cash equivalents were $146.7 million, current assets $147.6 million, current liabilities $6.3 million, total liabilities $8.9 million, and shareholders’ equity $141.3 million. Accumulated deficit was $232.6 million. The company had no outstanding loan balance; the $15 million SLR loan was repaid and terminated in June 2022. Operating lease liabilities totaled $2.4 million. No gross margin is meaningful because the company reported no revenue.
Changes versus prior comparable periods
- For the quarter, operating expenses rose 18% to $14.4 million; R&D increased 16% and G&A increased 28%. Net loss increased from $12.6 million to $13.6 million.
- For the six months, operating expenses increased 24% to $24.6 million and net loss rose from $20.4 million to $23.4 million. Higher staffing and share-based compensation drove much of the expense increase, alongside RZ358 manufacturing readiness and RZ402 trial spending.
- Six-month operating cash use increased from $13.5 million to $15.1 million. Financing cash inflow fell to $11.6 million from $54.9 million in the prior-year period; the current-period amount primarily reflects the July 2022 private placement.
- Interest income increased substantially as cash balances and interest rates rose. The company incurred no interest expense in the current six-month period after repaying its loan; the prior-year period included $0.9 million of interest expense.
Outlook, developments and risks
- RZ358: Phase 2b RIZE dosing was completed in the first half of 2022, with topline results announced in May 2022. The company planned regulatory discussions in the first half of 2023 and anticipated starting Phase 3 in summer 2023, with topline results targeted for the first quarter of 2025. These are forward-looking plans, not guarantees.
- RZ402: A Phase 2 DME study began in December 2022, designed to enroll about 100 participants across three dose groups and placebo. The company expected dosing completion in the fourth quarter of 2023 and results in the first quarter of 2024. Dosing the first patient on February 6, 2023 triggered a $3 million ActiveSite milestone, payable in February and to be expensed in the quarter ending March 31, 2023.
- Management stated cash at December 31, 2022 was expected to fund obligations and planned activities through at least February 2024 in the liquidity note. MD&A separately describes funding through the quarter ending December 31, 2023; this difference should be clarified. Management expects continuing operating losses and says additional financing may be needed over the longer term.
- License commitments include a $5 million XOMA milestone upon first-patient dosing in an RZ358 Phase 3 trial, which the company expected within 12 months; additional clinical and regulatory milestones and future royalties may apply. Further milestones are contingent on clinical or regulatory events.
- The company entered a headquarters lease extending to November 2027, with approximately $2.9 million in base rent. Cash was concentrated at financial institutions, with deposits exceeding federal insurance limits; $115.1 million was in a money-market fund at period end.
- Management reported a material weakness in internal control over financial reporting related primarily to inadequate segregation of duties due to limited staffing. New accounting software and additional personnel were intended to strengthen controls, but the company could not assure the weakness would be eliminated.
- No material litigation was reported. The filing identifies clinical, regulatory, financing, and execution risks; no material changes to the risk factors in the 2022 Form 10-K were reported.
Important facts for investors to verify
- Clarify the differing cash-runway statements: through December 2023 in MD&A versus at least February 2024 in the liquidity note.
- Reconcile the MD&A statement that remaining long-term milestone obligations total $72.5 million with the stated maximums of $35 million for XOMA and $32.5 million for ActiveSite, which total $67.5 million before accounting for milestones already triggered or paid.
- Track whether RZ358 Phase 3 and RZ402 Phase 2 timelines, enrollment, endpoints, and regulatory plans remain on schedule, and assess resulting milestone payments and cash needs.
- Monitor operating cash burn, future financing needs, equity dilution, and the status of the disclosed internal-control material weakness.